Clifford Chance advises UCB on IMIDomics deal
Clifford Chance has advised UCB, a biopharmaceutical company focused on immunology and neurology, has completed the acquisition of the IMIDomics Patient Insight Business, a curated patient data platform developed by IMIDomics, a biotechnology company specialising in immune-mediated inflammatory diseases.
The platform, built over many years through a global clinical network supported by the Vall d’Hebron Institute of Research (VHIR) in Barcelona, encompasses clinical information, biological samples and multi-omics datasets.
The team
Clifford Chance advised UCB on the cross-border transaction through a team spanning its Brussels, Barcelona and Madrid offices. The team was led by Patrice Viaene (Partner, Brussels) and José Maria Vilaseca (Senior Associate, Barcelona), and further comprised Katharine Missenden (Counsel, Brussels), Sébastien Nerincx (Associate, Brussels), Carme Briera (European Senior Counsel, Barcelona), Jorge Martín-Fernández (Counsel, Madrid), Olga Albalá (Associate, Madrid), Fernando Irurzun (Partner, Madrid), Ainhoa Rey (Associate, Barcelona), Adrián Crespo (Counsel, Barcelona), Fernando Escribano (Counsel, Madrid) and Estel Casas (Associate, Barcelona).
